Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)180.00
  • Today's Change2.35 / 1.32%
  • Shares traded433.21k
  • 1 Year change-9.30%
  • Beta1.7767
Data delayed at least 15 minutes, as of May 24 2024 16:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.

  • Revenue in DKK (TTM)6.64bn
  • Net income in DKK984.37m
  • Incorporated1992
  • Employees1.38k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nykode Therapeutics ASA73.09m-273.91m3.12bn176.00--2.85--42.71-1.42-1.420.37535.180.0534--91.80653,690.30-20.015.65-22.976.38-----374.7718.13----0.0313--79.99282.1717.75--187.37--
Calliditas Therapeutics AB842.21m-337.15m4.68bn219.00--54.59--5.55-9.78-9.7824.432.240.75413.168.976,723,169.00-30.19-26.46-38.05-30.2795.01---40.03-76.592.62-3.990.8943--50.32---13.08------
Surgical Science Sweden AB540.92m133.59m4.73bn265.0035.421.6127.828.754.084.0816.5189.920.17491.686.123,238,531.004.324.494.594.7868.5970.0624.7023.753.53--0.000.0010.0168.1424.47--38.57--
Gubra A/S205.01m-44.52m5.23bn219.00--10.87--25.52-2.91-2.9113.5129.44------936,095.90--------56.06---21.72------0.1296--2.82---1,133.04------
Swedencare AB (publ)1.55bn45.93m5.79bn552.00125.991.1623.503.730.45050.450515.2148.800.24122.359.524,966,461.000.71441.380.73611.4355.6455.342.965.101.822.210.174645.3327.4888.16-37.9620.2430.90--
BioGaia AB835.44m238.50m8.00bn211.0034.825.9631.469.573.683.6812.8821.470.5414----6,192,767.0015.4615.4716.8216.9373.3273.3028.5527.70----0.00104.4217.4411.81-2.2511.2029.2728.10
AddLife AB6.29bn50.75m8.57bn2.29k174.612.6713.101.360.64830.648380.4142.380.73933.625.534,258,149.000.61125.310.92998.8337.1636.890.82675.790.47781.480.517331.736.6231.30-60.428.0044.43-1.89
Bonesupport Holding AB421.26m171.24m10.69bn121.0062.6029.4060.0525.384.054.059.968.611.190.6576.366,245,276.0048.22-9.0861.41-11.2892.0190.2540.65-11.652.42--0.0282--79.7643.65459.44--18.39--
BioArctic AB162.02m-78.48m11.04bn90.00--20.77--68.17-1.38-1.382.8611.240.2202----2,866,000.00-10.662.24-11.672.5683.3886.52-48.449.76----0.00430.00169.83-2.912,150.71-9.6911.83--
Bavarian Nordic A/S6.64bn984.37m13.87bn1.38k13.821.368.802.0912.8612.8686.59130.350.49561.749.324,816,359.007.351.218.921.4860.9053.7214.824.061.03--0.04270.00124.1469.78524.66--35.76--
Vitrolife AB2.25bn-2.46bn16.06bn1.13k--1.89--7.15-28.33-28.3325.8497.730.18593.766.543,242,818.00-20.38-4.57-21.03-4.7856.3958.38-109.60-21.892.98-30.310.1353--8.6024.99-1,077.41---7.953.30
Camurus AB1.17bn289.39m20.38bn218.0070.6711.9968.2417.407.797.7931.7545.910.82651.146.658,557,742.0020.43-1.1323.79-1.4193.1790.0524.71-1.637.39--0.0086--79.52103.39676.63--16.29--
ALK-Abello A/S4.94bn555.00m31.40bn2.83k62.197.3136.856.352.492.4921.9321.190.7521.295.811,749,646.008.453.5010.364.3763.2560.6611.235.071.2350.270.09950.006.9410.6045.07--16.32--
Data as of May 24 2024. Currency figures normalised to Bavarian Nordic A/S's reporting currency: Danish Krone DKK

Institutional shareholders

20.96%Per cent of shares held by top holders
HolderShares% Held
ATP Arbejdsmarkedets Till�gspensionas of 31 Dec 20227.16m9.17%
The Vanguard Group, Inc.as of 09 May 20242.31m2.96%
Norges Bank Investment Managementas of 31 Dec 20231.64m2.10%
Dimensional Fund Advisors LPas of 09 May 20241.23m1.58%
BlackRock Fund Advisorsas of 09 May 20241.07m1.37%
Nykredit Bank A/S (Investment Management)as of 30 Apr 2024929.72k1.19%
Handelsbanken Fonder ABas of 30 Apr 2024628.95k0.81%
Victory Capital Management, Inc. (Investment Management)as of 31 Jan 2024609.35k0.78%
Oddo BHF Asset Management SASas of 30 Apr 2024443.99k0.57%
AllianceBernstein Ltd.as of 29 Feb 2024346.58k0.44%
More ▼
Data from 31 Dec 2023 - 15 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.